Showing results (31-40 of 40) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 40 results.
Human Gene Therapy|May 20, 1997
Intracranial administration of adenovirus expressing HSV-TK in combination with ganciclovir produces a dose-dependent, self-limiting inflammatory responseJ G Smith, S E Raper, E B Wheeldon, et al.
American Journal of Obstetrics and Gynecology|November 1, 1996
Adenovirus-mediated gene therapy of ovarian cancer in a mouse modelK Behbakht, I Benjamin, H C Chiu, et al.
Nuclear Medicine and Biology|October 2, 2001
A simplified one-pot synthesis of 9-[(3-[18F]fluoro-1-hydroxy-2-propoxy)methyl]guanine([18F]FHPG) and 9-(4-[18F]fluoro-3-hydroxymethylbutyl)guanine ([18F]FHBG) for gene therapyG G Shiue, C Y Shiue, R L Lee, et al.
Cancer Immunology, Immunotherapy : CII|August 5, 1998
Adenoviral transduction of melanoma cells with B7-1: antitumor immunity and immunosuppressive factorsH K Boxhorn, J G Smith, Y J Chang, et al.
Cancer Research|April 15, 1994
Use of recombinant adenovirus to transfer the herpes simplex virus thymidine kinase (HSVtk) gene to thoracic neoplasms: an effective in vitro drug sensitization systemW R Smythe, H C Hwang, K M Amin, et al.
Oncogene|December 22, 1999
Basic fibroblast growth factor induces a transformed phenotype in normal human melanocytesM Nesbit, H K Nesbit, J Bennett, et al.
European Journal of Nuclear Medicine|February 24, 2001
Imaging in vivo herpes simplex virus thymidine kinase gene transfer to tumour-bearing rodents using positron emission tomography andR Hustinx, C Y Shiue, A Alavi, et al.
Annals of Surgery|July 1, 1995
Treatment of experimental human mesothelioma using adenovirus transfer of the herpes simplex thymidine kinase geneW R Smythe, H C Hwang, A A Elshami, et al.
The New England Journal of Medicine|March 31, 1977
A randomized clinical trial of granulocyte transfusions for infection in acute leukemiaJ B Alavi, R K Root, I Djerassi, et al.
Neuro-Oncology|April 18, 2001
Importance of dose intensity in neuro-oncology clinical trials: summary report of the Sixth Annual Meeting of the Blood-Brain Barrier Disruption ConsortiumN D Doolittle, C P Anderson, W A Bleyer, et al.
Pageof 4